Loading patent…
AssigneesUniversidad de Caldas, Universidad de Antioquia, The Board of Trustees of Illinois State University
InventorsLuz Amalia Rios Vasquez, Rogelio Ocampo Cardona, Sandra Milena Duque, Sara Maria Robledo Restrepo, Ivan Dario Velez Bernal, David Leonardo Cedeño Medina, Marjorie Ann Jones
Estimating the term…
The use of quaternary halogenated ammonium salts for treating leishmaniasis infections and other parasitic diseases is described. Although there have been previous reports in which quaternary ammonium salts are used as antimalarial, antifungal, and antileishmanial compounds, the use of such salts containing a halogenated N-methyl substituent as a therapeutic agent against leishmaniasis had not been reported. The compounds described here, in specific those with a terminal arylalkenyl or diarylalkenyl moiety, are shown to inhibit the growth of Leishmania panamensis parasites, a known causative agent of leishmaniasis disease. In addition, the series of compounds are also extensive against malaria, Chagas disease, toxoplasmosis, and other parasitic diseases.
QUATERNARY N-(HALOMETHYL) AMMONIUM SALTS AS THERAPEUTIC AGENTS characterized by a series of compounds with general structure consisting of the form [XCH2—N+(R)(R′)—W-G]A− a quaternary N-(halomethyl) ammonium cation head, a tail G, a chemical tether W, and a counter ion A−.
QUATERNARY N-(HALOMETHYL) AMMONIUM SALTS AS THERAPEUTIC AGENTS characterized by a series of compounds with general structure consisting of the form [XCH2-N+(R)(R′)—W-G]A-, with the quaternary N-(halomethyl) ammonium cation head constituted by a nitrogen atom which is coordinated to four ligands with the following specific description:
QUATERNARY N-(HALOMETHYL) AMMONIUM SALTS AS THERAPEUTIC AGENTS characterized by a series of compounds with general structure consisting of the form [XCH2-N+(R)(R′)—W-G]A- where the tail G is a methyl group, a hydroxyl group, or an alkenyl system with groups V, Y and Z attached to the vinylic carbons;
QUATERNARY N-(HALOMETHYL) AMMONIUM SALTS AS THERAPEUTIC AGENTS characterized by a series of compounds with general structure consisting of the form [XCH2-N+(R)(R′)—W-G]A- where the terminal arylalkenyl or diarylalkenyl (i.e. G=alkenyl system with V=H, Y=H, Z=C6H5 or V=H, Y=C6H5, Z=H or V=H, Y=C6H5, Z=C6H5) were more effective against the parasites than those without this moiety.
Dependencies are inferred from the claim text.